Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia

American Journal of Cardiology

Volumn 91, Issue 5, 2003, Pages 604-606

  Trip, Mieke D ^a   Van Wissen, Sanne ^b   Smilde, Tineke J ^b   Hutten, Barbara A ^b   Stalenhoef, Anton F H ^b   Kastelein, John J P ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EUREQUA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANK SUM TEST; STATISTICAL ANALYSIS; TREATMENT OUTCOME; ULTRASOUND; WILCOXON SIGNED RANKS TEST;

EID: 0037374112     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)03318-0     Document Type: Article

References (14)

1. Rosenson R.S., Tangney C.C. Antithrombotic properties of statins implications of cardiovascular event reduction . JAMA. 279:1998;1643-1650.
2. Joukhadar C., Klein N., Prinz M., Schrolnberger C., Vukovich T., Wolzt M., Schmetterer L., Dorner G.T. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost. 85:2000;47-51.
3. Koh K.K. Effects of HMG-CoA reductase inhibitor on hemostasis. Int J Cardiol. 76:2000;23-32.
4. Rosenson R.S., Tangney C.C., Schaefer E.J. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis. 155:2001;463-466.
5. Davidson M., McKenney J., Stein E., Schrott H., Bakker-Arkema R., Fayyad R., Black D. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 79:1997;1475-1481.
6. Marais A.D., Firth J.C., Bateman M.E., Byrnes P., Martens C., Mountney J. Atorvastatin an effective lipid-modifying agent in familial hypercholesterolemia . Arterioscl Thromb Vasc Biol. 17:1997;1527-1531.
7. Wierzbicki A.S., Lumb P.J., Semra Y.K., Crook M.A. Effect of atorvatsatin on plasma fibrinogen. Lancet. 351:1998;569-570.
8. Wierzbicki A.S., Lumb P.J., Chik G., Crook M.A. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familiar hypercholesterolemia. Int J Clin Pract. 53:1999;609-611.
9. Bertolotto A., Bandinelli S., Ruocco L., Faro A.L., Penno G., Navalesi R. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia. Atherosclerosis. 143:1999;455-457.
10. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J.P., Stalenhoef A.H.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP) a prospective, randomised, double-blind trial . Lancet. 357:2001;577-581.
11. Hodis H.N., Mack W.J., LaBree L., Selzer R.H., Liu C., Azen S.P. The role of carotid arterial intima media thickness in predicting clinical coronary events. Ann Intern Med. 128:1998;262-269.
12. Smilde T.J., Trip M.D., Wollersheim H., van Wissen S., Kastelein J.J.P., Stalenhoef A.F.H. Rationale, design and baseline characteristics of a clinical trial comparing the effects of robust versus conventional cholesterol lowering and intima media thickness in patients with familial hypercholesterolaemia. The Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study. Clin Drug Investig. 20:2001;67-69.
13. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogenes. Acta Haematol. 17:1957;237-246.
14. Gotto A.M. Jr. Triglycerides as a risk factor for coronary artery disease. Am J Cardiol. 82:1998;22Q-25Q.